DarioHealth Corp. (DRIO) Is At $1.45 Formed Wedge; 4 Analysts Covering Bayer Aktiengesellschaft (BAYRY)

DarioHealth Corp. (DRIO) formed wedge down with $1.33 target or 8.00% below today’s $1.45 share price. DarioHealth Corp. (DRIO) has $20.07 million valuation. The stock decreased 4.61% or $0.07 during the last trading session, reaching $1.45. About 77,286 shares traded. DarioHealth Corp. (NASDAQ:DRIO) has declined 46.73% since February 6, 2017 and is downtrending. It has underperformed by 63.43% the S&P500.

Among 6 analysts covering Bayer AG (OTCMKTS:BAYRY), 4 have Buy rating, 1 Sell and 1 Hold. Therefore 67% are positive. Bayer AG had 8 analyst reports since September 21, 2015 according to SRatingsIntel. Zacks downgraded the shares of BAYRY in report on Monday, September 21 to “Sell” rating. The company was downgraded on Friday, October 30 by HSBC. Citigroup downgraded the stock to “Neutral” rating in Wednesday, December 2 report. The firm has “Buy” rating given on Thursday, August 25 by Citigroup. As per Thursday, December 10, the company rating was upgraded by HSBC. The rating was upgraded by Jefferies on Monday, December 19 to “Buy”. The firm earned “Neutral” rating on Tuesday, January 5 by JP Morgan. The company was upgraded on Wednesday, December 7 by UBS. See Bayer Aktiengesellschaft (OTCMKTS:BAYRY) latest ratings:

The stock decreased 5.45% or $1.72 during the last trading session, reaching $29.865. About shares traded. Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has 0.00% since February 6, 2017 and is . It has underperformed by 16.70% the S&P500.

Bayer Aktiengesellschaft operates as a life science firm worldwide. The company has market cap of $92.32 billion. The firm operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro divisions. It has a 10.87 P/E ratio. The Pharmaceuticals segment offers prescription products primarily for cardiology and womenÂ’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: